TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19093917

Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention (individualized session with supportive phone calls every 4 months for 2 years and annual lectures on physical activity)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 632
Study: 16613927

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 54

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 54
Study: 15562739

Group type: EXPERIMENTAL
Intervention: Synthetic leather mask
Number of subjects: 900

Group type: COMPARATOR
Intervention: Adhesive tape
Number of subjects: 900

Group type: COMPARATOR
Intervention: Cotton band
Number of subjects: 900
Study: 11113686

Group type: EXPERIMENTAL
Intervention: Pioglitazone at 30 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Glibenclamide at 5 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Voglibose at 0.6 mg/day
Number of subjects: 45
Study: 8669673

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 0.5% bupivacaine (2-4 ml)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ice-cold lactated Ringer's solution administered intravenously before spinal blockade
Number of subjects: 11
Study: 7952483

Group type: EXPERIMENTAL
Intervention: Glutathione (200 mg/kg) administered before cardiopulmonary bypass and on the first and second postoperative days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (same volume as glutathione)
Number of subjects: 10
Study: 3111931

Group type: EXPERIMENTAL
Intervention: Misoprostol 2 X 400 micrograms
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Misoprostol 2 X 200 micrograms
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 31099474

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% q8h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical brinzolamide 1% q8h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% q12h combined with dorzolamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% q12h combined with brinzolamide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topical timolol 0.5% q12h
Number of subjects: 10
Study: 29579490

Group type: EXPERIMENTAL
Intervention: CONNECT program (psychosocial intervention)
Number of subjects: 34
Study: 28167482

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50mg twice a day for twelve weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Metformin 850mg twice a day for twelve weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 70
Study: 23633187

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administered before skin incision
Number of subjects: 65

Group type: COMPARATOR
Intervention: Prophylactic antibiotics administered after obtaining operative cultures
Number of subjects: 65
Study: 23108892

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1,250 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus Gemcitabine (Gem)
Number of subjects: 58
Study: 21960587

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (annual treatment)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Standard first-line ITP therapy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Surviving patients post-ITP treatment
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Monitoring plan for ITP
Number of subjects: 216
Study: 18926826

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/d
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16855193

Group type: EXPERIMENTAL
Intervention: Energy restriction (62% energy restriction for 2 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ad libitum food intake after energy restriction
Number of subjects: 35
Study: 14648409

Group type: EXPERIMENTAL
Intervention: DoubleLayer stent (DLS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Polyethylene stent (PE)
Number of subjects: 120
Study: 10802775

Group type: EXPERIMENTAL
Intervention: Linomide (1.0, 2.5, or 7.5 mg orally daily)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715
Study: 8835114

Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP)
Number of subjects: 0
Study: 1362436

Group type: EXPERIMENTAL
Intervention: 0.5% dapiprazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3095410

Group type: EXPERIMENTAL
Intervention: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control solution (isotonic saline, 0.9% w/v)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Allergen solution (freeze-dried allergen extract reconstituted with isotonic saline) in nonatopic control subjects
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control solution (isotonic saline, 0.9% w/v) in nonatopic control subjects
Number of subjects: 12
Study: 29294930

Group type: EXPERIMENTAL
Intervention: Wingman 101 program
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-program control condition
Number of subjects: 80
Study: 30715932

Group type: EXPERIMENTAL
Intervention: Computer-Controlled Local Anesthetic Device (CCLAD) in upright position
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Computer-Controlled Local Anesthetic Device (CCLAD) in supine position
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional syringe (compared to CCLAD)
Number of subjects: 110
Study: 27417903

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX)
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Placebo (stopping CTX)
Number of subjects: 2180
Study: 24509190

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1057
Study: 22885014

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine administered sequentially 21 days before first dose (N=73)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine administered sequentially 21 days after second dose (N=72)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine co-administered first dose (N=84)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pmd09 vaccine co-administered second dose (N=84)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Trivalent seasonal influenza vaccine (TIV)
Number of subjects: 313
Study: 19782973

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH) method with injected hydrostatic pressure after thawing
Number of subjects: 0

Group type: COMPARATOR
Intervention: No assisted hatching (control group)
Number of subjects: 0
Study: 18248643

Group type: EXPERIMENTAL
Intervention: Metformin treatment (1500 mg/day orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ghrelin injection
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline NPY levels
Number of subjects: 14
Study: 16277714

Group type: EXPERIMENTAL
Intervention: APACHE II scoring errors
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Inter-observer reliability
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: AP2 score misclassification
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: AP2 score cut-off of 25
Number of subjects: 56
Study: 12610021

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after acute smoking (smokers smoked three cigarettes immediately before insulin administration)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after nonacute smoking (smokers had not smoked since midnight)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after acute smoking (smokers)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (33.8 IU) administered after nonacute smoking (smokers)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inhaled insulin (33.8 IU) administered to nonsmokers
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inhaled insulin (33.8 IU) administered to smokers
Number of subjects: 43
Study: 10726229

Group type: EXPERIMENTAL
Intervention: Low doses of polyethylene glycol solutions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Large doses of polyethylene glycol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three administrations of polyethylene glycol in a three‐day period
Number of subjects: 30
Study: 7731143

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1664106

Group type: EXPERIMENTAL
Intervention: Hashish (200 mg hashish with 11.5% THC per 1 g tobacco cigarette)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7005872

Group type: EXPERIMENTAL
Intervention: nicergoline 30 mg/day divided into 6 doses
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 31732300

Group type: EXPERIMENTAL
Intervention: Lianhuaqingwen (LHQW) granules
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 31181266

Group type: EXPERIMENTAL
Intervention: Behavioral economic tools/processes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28466396

Group type: EXPERIMENTAL
Intervention: Counseling practices by pharmacists
Number of subjects: 129
Study: 26062192

Group type: EXPERIMENTAL
Intervention: Subgaleal acupoint injection with metoclopramide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral administration of flunarizine (2.5 mg each time, once every night for 3 months)
Number of subjects: 64
Study: 22431239

Group type: EXPERIMENTAL
Intervention: PF sirolimus-eluting stent (PF-SES)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Permanent polymer paclitaxel-eluting stent (PES)
Number of subjects: 450
Study: 21555967

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 3 consecutive injections of 1.25 mg given 6 weeks apart.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Combined intravitreal bevacizumab and triamcinolone (IVB/IVT) - first injection combined with 2 mg of triamcinolone.
Number of subjects: 115

Group type: COMPARATOR
Intervention: IVB/IVT group
Number of subjects: 115
Study: 19215749

Group type: EXPERIMENTAL
Intervention: Medical model with risk assessment and management strategies for caries prevention and management
Number of subjects: 0
Study: 18077838

Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-course antenatal zidovudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nevirapine use
Number of subjects: 0
Study: 15378428

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11223703

Group type: EXPERIMENTAL
Intervention: GDM patients (hyper-, normo-, hypoinsulinemic)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GDM patients (hypo- and normoinsulinemic)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normo- and hypoinsulinemic GDM patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic GDM patients
Number of subjects: 22
Study: 9620242

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (accelerated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionation
Number of subjects: 0
Study: 7979117

Group type: EXPERIMENTAL
Intervention: Low dose ketamine by subcutaneous infusion (0.1 mg.kg‐1.h‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine by subcutaneous infusion (0.03 mg.kg‐1.h‐1)
Number of subjects: 60
Study: 2532383

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol after Ipratropium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium after Salbutamol
Number of subjects: 12
Study: 989373

Group type: EXPERIMENTAL
Intervention: D‐Amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesoridazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptin
Number of subjects: 0
Study: 30506499

Group type: EXPERIMENTAL
Intervention: TTFields plus temozolomide (TTFields/TMZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study: 27796647

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of piperacillin/tazobactam (4/0.5 g over 3 hours every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent infusion (II) of piperacillin/tazobactam (4/0.5 g over 30 minutes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extended infusion (EI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent infusion (II)
Number of subjects: 50
Study: 25262475

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study: 23754254

Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES; Xience)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Sirolimus‐eluting stents (SES; Cypher)
Number of subjects: 377
Study: 21575503

Group type: EXPERIMENTAL
Intervention: CPT‐11 + CAP (irinotecan 100 mg/m² on days 1 and 8; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: L‐OHP + CAP (oxaliplatin 100 mg/m² on day 1; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Number of subjects: 63
Study: 18650513

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Raltegravir with darunavir or enfuvirtide
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo with darunavir or enfuvirtide
Number of subjects: 462
Study: 16567600

Group type: EXPERIMENTAL
Intervention: Disclosure intervention (mailed compensation disclosure letter)
Number of subjects: 8000
Study: 12626469

Group type: EXPERIMENTAL
Intervention: High carbohydrate availability (HC) - 9.32 +/- 0.08 g.kg(-1).day(-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low carbohydrate availability (LC) - 0.59 +/- 0.21 g.kg(-1).day(-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low carbohydrate availability (LC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High carbohydrate availability (HC)
Number of subjects: 6
Study: 11111812

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) therapy using fresh frozen plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryosupernatant
Number of subjects: 0
Study: 9074537

Group type: EXPERIMENTAL
Intervention: Active chronic cocaine users
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15
Study: 8403637

Group type: EXPERIMENTAL
Intervention: Ilizarov external fixator with gentamicin methylmethacrylate bead (GMB) and intravenous antibiotics (Group 2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ilizarov external fixator with initial debridement and intravenous antibiotics (Group 1)
Number of subjects: 18
Study: 3510323

Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts to the popliteal artery
Number of subjects: 845

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts to the popliteal artery
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts above-knee
Number of subjects: 845

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts above-knee
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts below-knee
Number of subjects: 845

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts below-knee
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts infrapopliteal
Number of subjects: 845

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts infrapopliteal
Number of subjects: 845

Group type: COMPARATOR
Intervention: Obligatory infrapopliteal PTFE grafts
Number of subjects: 845
Study: 29148345

Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 440
Study: 29124500

Group type: EXPERIMENTAL
Intervention: Internet-based unguided self-help psychosocial intervention (BADI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 284
Study: 26296448

Group type: EXPERIMENTAL
Intervention: IR/ER OC/APAP
Number of subjects: 1106

Group type: COMPARATOR
Intervention: IR OC/APAP
Number of subjects: 1106

Group type: COMPARATOR
Intervention: IR tramadol HCl/APAP
Number of subjects: 1106

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1106
Study: 26054181

Group type: EXPERIMENTAL
Intervention: Colgate ProClinical C200 toothbrush with triple clean head
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colgate ProClinical C200 toothbrush with sensitive head
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual flat‐trim toothbrush (Oral B Indicator toothbrush)
Number of subjects: 120
Study: 21847569

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 40 mg orally twice daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: LY404039 (single intraperitoneal injection)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate (acute dosing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate (dosed for 7 days)
Number of subjects: 16
Study: 19806426

Group type: EXPERIMENTAL
Intervention: NSAID plaster
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 165
Study: 17662919

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 16416370

Group type: EXPERIMENTAL
Intervention: Referral to the specialized pediatric nephrology unit within the first year of life
Number of subjects: 43

Group type: COMPARATOR
Intervention: Referral to the specialized pediatric nephrology unit after the first year of life
Number of subjects: 43
Study: 12571526

Group type: EXPERIMENTAL
Intervention: Prototype informed consent process
Number of subjects: 4892

Group type: COMPARATOR
Intervention: Baseline knowledge
Number of subjects: 4892
Study: 10408998

Group type: EXPERIMENTAL
Intervention: Mailed reminders (sent at 3 weeks after the visit)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 200
Study: 8887291

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone hemodialysis (HfPS-HD)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: High-flux polysulfone hemodiafiltration (HfPS-HDF)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Cuprophan hemodialysis (Cu-HD)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Low-flux polysulfone hemodialysis (LfPS-HD)
Number of subjects: 380
Study: 1857139

Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing randomization
Number of subjects: 0
Study: 6352780

Group type: COMPARATOR
Intervention: Albuterol (inhalations from a metered dose inhaler) - 1, 2, 4, 6, and 8 inhalations
Number of subjects: 44

Group type: COMPARATOR
Intervention: Albuterol (delivered by IPPB) - 1.25, 2.5, 5, 10, and 15 mg
Number of subjects: 44
Study: 30316200

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30356287

Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Treatment)
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Recent HIV infections (ARV-naïve individuals with detectable HIV-1 RNA >400 copies/mL)
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence (overall population)
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence (younger subset 16–49 years)
Number of subjects: 12610
Study: 27138295

Group type: EXPERIMENTAL
Intervention: Tramadol extended release (ER) 25 to 100 mg
Number of subjects: 75
Study: 24506852

Group type: COMPARATOR
Intervention: Modified surviving sepsis bundles group (n=42) with PiCCO catheter and fluid resuscitation guided by ITBVI (850-1000 mL/m²), dobutamine for heart function, norepinephrine for MAP maintenance, and monitoring of extra-vascular lung water.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard surviving sepsis bundle group (n=40) receiving standard EGDT bundles.
Number of subjects: 82
Study: 22139005

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 42
Study: 20236862

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin or follicle‐stimulating hormone following the long gonadotrophin‐releasing hormone agonist protocol
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Best predictive model using age, duration of infertility, infertility diagnosis, endometrial thickness, pre‐stimulation total testosterone and sex hormone‐binding globulin concentrations
Number of subjects: 731
Study: 17561808

Group type: EXPERIMENTAL
Intervention: Lower body muscle tensing (LBMT)
Number of subjects: 20
Study: 15853445

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin
Number of subjects: 12231

Group type: COMPARATOR
Intervention: Comparator antibacterial (cefuroxime, clarithromycin)
Number of subjects: 12231
Study: 12109763

Group type: EXPERIMENTAL
Intervention: Recent information reliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrative judgment
Number of subjects: 0
Study: 10703404

Group type: EXPERIMENTAL
Intervention: Hospital-based designated requestor program (8-hour training)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Organ procurement coordinator approach
Number of subjects: 13
Study: 7580666

Group type: EXPERIMENTAL
Intervention: Feedback of information on control of asthma
Number of subjects: 818

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 818